Improving
Download
1 / 1

INTRODUCTION - PowerPoint PPT Presentation


  • 68 Views
  • Uploaded on

Improving solubility and cellular absorption of Paclitaxel with solid lipid nanoparticles and cyclodextrin Jong-Suep Baek , Jae-Woo So, Ji-Sook Hwang, Cheong-Weon Cho College of Pharmacy, Chungnam National University, Daejeon 305-764, South Korea. INTRODUCTION. 3. Surface tension.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' INTRODUCTION' - freja


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Improvingsolubility and cellular absorption of Paclitaxel with solid lipid nanoparticles and cyclodextrin

Jong-Suep Baek, Jae-Woo So, Ji-Sook Hwang, Cheong-Weon Cho

College of Pharmacy, Chungnam National University, Daejeon 305-764, South Korea.

INTRODUCTION

3. Surface tension

Paclitaxel (PTX), the first of a new class of microtubule stabilizing agents, is recognized as an effective chemotherapeutic agent for a wide variety of solid tumors. Clinical application of this highly effective drug in the treatment of cancer is limited because of its poor aqueous solubility and poor oral bioavailability. Therefore, PTX-incorporated SLN, PTX-HPCD and surface-modified PTX-incorporated SLN were prepared and evaluated by the physicochemical and biopharmaceutical characterization in this study. The major peaks of PTX were disappeared in the FT-IR spectra for surface-modified PTX-incorporated SLN. The BET surface area of PTX –incorporated SLN (PS3), and surface-modified PTX-incorporated SLN (FM4) was 4.09 m2/g and 4.79 m2/g, respectively. Based on the increase of BET surface area of FM4 compared to that of PS3, FM4 showed a 20% of dissolution and the cellular uptake of 29-fold increase compared to that of PS3. Taxol formulation showed 78% of cell viability and FM4 showed 72% of cell viability with 10uM of PTX, indicating FM4 did not show the higher toxicity compared to Taxol formulation. Therefore, FM4 could be good carrier for improving solubility and cellular absorption of water insoluble drug.

* Both lecithin and poloxamer 188 samples, tension was lowest at 75mg

Fig 4. Surface tension values of SLN with different surfactant amount

4. DSC and XRD

(A) (B)

AIMS

Solubility

III

IV

I

II

Fig 5. DSC (A) and XRD (B)

  • After making the SLN formulation, the lipid’s crystallinity was decreased.

  • SLN

  • HPCD

  • SLN+HPCD

5. FT-IR

PTX : low solubility

low permeability

(A) (B)

  • PTX

  • HPCD

  • PTX incorporated into HPCD

  • Physical mixture

  • PTX

  • Lipid

  • SLN

  • SLN+HPCD

  • SLN+HPCD (physical mixture)

Permeability

Fig 1. low permeability and low solubility of paclitaxel in BCS class

1. Preparation of SLN and SLN+HPCD

EXPERIMENTAL METHOD

Stearic acid (Lipid)

10mg PTX in EtOH

Fig 6. FT-IR spectra of HPCD (A) and SLN+HPCD (B)

(A) Intensity of the PTX major peak (1730cm-1, 1250cm-1) was reduced in the case of HPCD incorporation. It was evidence of an interaction at the solid state between PTX and HPCD.

(B) Intensity of the lipid major peak (2850cm-1 , 1670cm-1) was reduced in the case of SLN+HPCD. It was evidence that lipid’s surface was surrounded by HPCD.

Surfactant

(Poloxamer 188

and lecithin)

70℃ water bath

Emulsifying step

Sonification 15 min in 70 ℃ water bath

6. Cellular uptake study

Injection speed

- 1.5mL/min

1. Taxol and HPCD was below the LOQ (<0.015%)

2. In case of SLN, Uptake % of PTX was 0.129 (±0.046)%

3. In case of SLN+HPCD, Uptake % was 29 times higher than that of SLN

4℃ 10% mannitol

Cooling step

Sonification 15 min in 4 ℃ water bath

  • 1. Solubility and in vitro release

  • 2. SEM and particle characteristics

10% HPCD

Freeze-drying step

Fig 7. Caco-2 cellular uptake of each formula

Freeze-drying

7. Cytotoxicity study

  • 5uM as a loading concentration of cellular uptake study was optimal. (72 % viability in SLN+HPCD)

  • IC50 of each formulation is approximately 10~100uM.

  • Because of high permeability of PTX+HPCD, it has more toxicity than Taxol at Caco-2 cell line.

RESULTS AND DISCUSSION

Table 1. Solubility of each formulation

Fig 8. Caco-2 cell cytotoxicity study of SLN+HPCD and Taxol

a) b) c)

  • IC50 of SLN+HPCD is approximately 10M.

Fig 2. Dissolution profile of PTX

  • Considering the low solubility of PTX, these formulations significantly increased the PTX solubility.

  • During 36 hours, SLN-HPCD has the highest dissolution profile.

Fig 9. HeLA cell cytotoxicity study of SLN and SLN+HPCD

(A) (B) (C)

Table 2. Physical characteristic

CONCLUSIONS

Fig 3. SEM images

of PTX (A), SLN (B), SLN+HPCD (C)

  • For improving solubility and increasing cellular uptake of PTX into Caco-2 cells, PTX-incorporated SLN, PTX-HPCD and surface-modified PTX-incorporated SLN were prepared and evaluated by the physicochemical and biopharmaceutical characterization. The major peaks of PTX were disappeared in the FT-IR spectra for surface-modified PTX-incorporated SLN. Surface-modified PTX-incorporated SLN with HPCD showed a 20% of dissolution and the cellular uptake of 29-fold increase compared to that of PTX-incorporated SLN.

  • Particles revealed spherical shape and SLN+HPCD has smaller particle size than SLN.

  • Zeta value was enough to keep in stable status of particles.


ad